Measurement properties of quality‐of‐life outcome measures for children and adults with eczema: An updated systematic review

Abstract

ObjectiveThe aim of this updated systematic review was to systematically assess the measurement properties of previously discussed and new quality‐of‐life patient‐reported outcome measures (PROMs) in children and adults with eczema using the new COSMIN guideline.MethodsA systematic literature search was conducted in PubMed and EMBASE. Eligible studies reported on measurement properties of quality‐of‐life PROMs for children and adults with eczema. The methodological quality of selected already known PROMs and new evidence identified through the literature search was assessed with the COSMIN Risk of Bias checklist. The adequacy of included PROMs was judged with updated quality criteria, and the quality of evidence of the summarized results was graded. Finally, PROMs were placed in a recommendation category (A‐C).ResultsIn total, 133 measurement properties of nine different PROMs were assessed. No PROM could be placed in category A due to a lack of validation studies. Only the DLQI fulfilled the criteria for category C and therefore should not be recommended for use. All other PROMs were placed in category B, that is, they still have the opportunity to be recommended, but need further validation.ConclusionsCurrently, no PROM for quality of life can be recommended for use in children and adults with eczema. Further validation is needed. The DLQI cannot be recommended for future use.

Current measures are not sufficient: an interview‐based qualitative assessment of quality of life in cutaneous T‐cell lymphoma*

“…As in other disease areas such as atopic dermatitis and psoriasis, identifying the most appropriate patient-reported outcome instruments is important to ensure standardization in clinical trials and to establish standards of care in clinical practice for patients with CTCL. [21][22][23][24] Additionally, this study highlights the need for integration of mental health services into the multidisciplinary care of patients with CTCL in order to better address issues of self-image, social isolation and psychological distress.…”

“…Moving forward, incorporating these findings that distinguish patients with CTCL from other patient populations will be paramount in developing a comprehensive disease‐specific instrument that adequately captures their illness experience. As in other disease areas such as atopic dermatitis and psoriasis, identifying the most appropriate patient‐reported outcome instruments is important to ensure standardization in clinical trials and to establish standards of care in clinical practice for patients with CTCL 21–24 …”

Hyperhidrosis Quality of Life Index (HidroQoL©): further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial*

“…Even the DLQI has several serious issues, e.g. double‐barrelled and redundant items and evidence for insufficient measurement properties 31,32 . In this study, data were collected across multiple countries using different language versions of the HidroQoL.…”

Association between hospital‐diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood*

“…Clinical trials have shown that a reduction in AD severity correlates well with improvement in quality-of-life scores and decrease in anxiety and depression scores, in turn, indicating that these symptoms are reversible. 34,35 However, unfortunately, the quality-of-life outcomes typically used tend to be insufficiently sensitive to change, 36,37 making it difficult to measure the true effect of AD treatment on the psychiatric symptoms.…”